Equities

Clene Inc.

Clene Inc.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.69
  • Today's Change-0.20 / -3.40%
  • Shares traded95.50k
  • 1 Year change-31.61%
  • Beta0.3893
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments352350
Total Receivables, Net1.342.971.61
Total Inventory0.040.040.04
Prepaid expenses----2.47
Other current assets, total2.482.870.17
Total current assets392955
Property, plant & equipment, net13158.42
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets524463
LIABILITIES
Accounts payable1.503.011.92
Accrued expenses4.304.353.96
Notes payable/short-term debt4.8800
Current portion long-term debt/capital leases156.490.15
Other current liabilities, total----0
Total current liabilities25146.03
Total long term debt7.151919
Total debt272619
Deferred income tax----0
Minority interest------
Other liabilities, total6.478.1125
Total liabilities394150
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital256196176
Retained earnings (accumulated deficit)(243)(193)(163)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.200.200.23
Total equity133.2413
Total liabilities & shareholders' equity524463
Total common shares outstanding6.423.743.12
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.